Providence Capital Advisors LLC lifted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 52.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,214 shares of the pharmaceutical company’s stock after acquiring an additional 12,492 shares during the quarter. Providence Capital Advisors LLC’s holdings in GlaxoSmithKline were worth $1,449,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in GSK. Comerica Securities Inc. boosted its stake in GlaxoSmithKline by 2.6% in the fourth quarter. Comerica Securities Inc. now owns 12,984 shares of the pharmaceutical company’s stock worth $502,000 after purchasing an additional 326 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of GlaxoSmithKline by 5.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,769,859 shares of the pharmaceutical company’s stock worth $67,626,000 after acquiring an additional 88,148 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of GlaxoSmithKline by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 424,397 shares of the pharmaceutical company’s stock worth $16,216,000 after acquiring an additional 48,476 shares during the last quarter. Gabelli Funds LLC lifted its position in shares of GlaxoSmithKline by 22.7% during the first quarter. Gabelli Funds LLC now owns 13,500 shares of the pharmaceutical company’s stock worth $564,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Gamco Investors INC. ET AL acquired a new position in shares of GlaxoSmithKline during the first quarter worth approximately $1,888,000. 11.16% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages recently weighed in on GSK. Morgan Stanley reissued an “underweight” rating on shares of GlaxoSmithKline in a report on Monday, June 17th. ValuEngine downgraded GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Tuesday. Jefferies Financial Group reiterated a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, August 29th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, August 13th. Finally, Societe Generale upgraded GlaxoSmithKline from a “sell” rating to a “buy” rating in a research report on Tuesday, September 3rd. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $41.79.

Shares of NYSE GSK traded down $0.07 during mid-day trading on Wednesday, hitting $40.82. The company’s stock had a trading volume of 2,766,307 shares, compared to its average volume of 2,143,420. GlaxoSmithKline plc has a one year low of $36.41 and a one year high of $42.49. The company’s fifty day simple moving average is $41.16 and its 200-day simple moving average is $40.58. The company has a debt-to-equity ratio of 7.86, a current ratio of 0.71 and a quick ratio of 0.48. The stock has a market cap of $101.49 billion, a price-to-earnings ratio of 12.92, a price-to-earnings-growth ratio of 1.99 and a beta of 0.70.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. The business had revenue of $10.04 billion during the quarter, compared to the consensus estimate of $9.55 billion. On average, sell-side analysts predict that GlaxoSmithKline plc will post 2.96 EPS for the current year.

In other GlaxoSmithKline news, Director Plc Glaxosmithkline acquired 333,333 shares of GlaxoSmithKline stock in a transaction on Monday, July 1st. The shares were purchased at an average cost of $15.00 per share, with a total value of $4,999,995.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.00% of the stock is currently owned by company insiders.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.